# SIGNATURES OF CANNABIS ABUSE IN NEUROHIV (SCAN): AN INTEGRATED MOLECULAR AND IMAGING APPROACH

> **NIH NIH R01** · FATHER FLANAGAN'S BOYS' HOME · 2021 · $930,534

## Abstract

Project Summary/Abstract
HIV-infected adults in the western world have a life expectancy near that of the general population, but are at a
significantly elevated risk of developing cognitive deficits. Such impairments are the most common neurological
complication of HIV disease, with prevalence estimates ranging from 35-70% of all HIV-infected individuals,
and research targeting such comorbidities has been identified as a top priority by the Office of AIDS Research
(NOT-OD-15-137). Substance use disorders (SUD) are also more prevalent in the HIV-infected population, yet
their relative contribution to the increased rate of cognitive impairment in this group remains poorly understood.
A key barrier to progress in this area has been the historic lack of diagnostic tests and biomarkers that can
precisely assess the neurological complications of HIV-infection, which has all but precluded quantification of
the additive impact of SUD comorbidity. This barrier is central to RFA-DA-18-023, which requests applications
that “foster biomarker and signature identification that could advance the clinical assessment of the degree of
deterioration or damage, of functional reserve, and of resilience of host defense mechanisms, towards HIV-
infection and comorbidity of HIV with SUDs.” Specifically, the RFA requests proposals that identify biomarkers
derived from blood, plasma, noninvasive neuroimaging modalities, and/or other sources, with an emphasis on
biomarkers that can be quantitated, with levels assessed for their ability to predict disease progression.
The current project directly targets the scientific gaps identified in this RFA, Identification of Biomarkers of HIV
Pathogenesis and Substance Abuse Comorbidity, using a multipronged approach that includes state-of-the-art
neurophysiological, structural, and spectroscopic noninvasive imaging, cognitive assessment, and cellular and
molecular analyses of blood/plasma in the context of cannabis use disorder (CUD). Specifically, the Signatures
of Cannabis Abuse in NeuroHIV (SCAN) Consortium will utilize advanced magnetoencephalographic (MEG)
imaging to quantify the neural dynamics serving cognitive processing, 3-Tesla MRI and multimodal parcellation
methods to map brain architecture, functional MRI (fMRI) for hemodynamics and intrinsic networks, and 7-Tesla
spectroscopic imaging to quantify local GABA levels across the brain. These data will be integrated with a
comprehensive molecular screen that includes 35 plasma biomarkers covering the immune, inflammatory,
coagulation, endothelial, and neurological systems, a 10-color flow cytometry panel delineating CD4 and CD8
T cells, B cells, NK cells, monocyte subsets, and activation markers, known clinical markers, and mitochondrial
function in immune cells using the Seahorse Analyzer method. To enhance rigor, demographically-matched
groups of uninfected controls with and without CUD will be enrolled, which will enable the interaction of HIV and
CUD to be quantified. ...

## Key facts

- **NIH application ID:** 10197080
- **Project number:** 5R01DA047828-05
- **Recipient organization:** FATHER FLANAGAN'S BOYS' HOME
- **Principal Investigator:** JAMES T. BECKER
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $930,534
- **Award type:** 5
- **Project period:** 2018-09-15 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10197080

## Citation

> US National Institutes of Health, RePORTER application 10197080, SIGNATURES OF CANNABIS ABUSE IN NEUROHIV (SCAN): AN INTEGRATED MOLECULAR AND IMAGING APPROACH (5R01DA047828-05). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10197080. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*